Factors associated with glycemic control in adult type 1 diabetes patients treated with insulin pump therapy
- 452 Downloads
Continuous subcutaneous insulin infusion (CSII) by insulin pump seems to improve glycemia and quality of life as compared to conventional insulin therapy in type 1 diabetes (T1DM). However, while many T1DM subjects achieve excellent glycemic control, some others cannot reach recommended goals. In a retrospective analysis, we searched for factors associated with glycemic control in T1DM patients treated with insulin pump therapy. Data from 192 patients (133 women and 59 men) treated with personal insulin pumps at the Department of Metabolic Diseases, University Hospital, Krakow, Poland were analyzed. Sources of information included medical records, memory read-outs from insulin pumps and data from glucose meters. Univariate, multivariate linear and logistic regression analysis for the association with hemoglobin A1c (HbA1c) level were performed. The mean age of the subjects was 28.9 (±11.2) years, the mean duration of T1DM—14.6 (±7.6) years, mean body mass index—23.5 (±3.1) kg/m2. The mean HbA1c level in the entire study group was 7.4 % (57 mmol/mol). In the multivariate linear regression analysis, HbA1c correlated with the mean number of daily blood glucose measurements, number of hypoglycemic episodes per 100 blood glucose measurements, age at the examination, and continuous glucose monitoring system use. Multivariate logistic regression analysis for reaching the therapeutic target of HbA1c < 7.0 % (53 mmol/mol) showed that the independent predictors of achieving this goal included the same four variables. In a large clinical observation, we identified that patient-related and technological factors associated with glycemic control in adult pump-treated T1DM subjects.
KeywordsType 1 diabetes mellitus Insulin pump HbA1c
The authors are grateful to Ms Aleksandra Malecka (Warsaw University) for her editorial and linguistic assistance.
Conflict of interest
Bartłomiej Matejko, Tomasz Klupa received payments for lectures from Medtronic. Katarzyna Cyganek received travel grants from Medtronic and Willcare.
This observational research complies with the current laws of Poland.
- 3.K. Jeitler, K. Horvath, A. Berghold, T.Z. Gratzer, K. Neeser, T.R. Pieber, A. Siebenhofer, Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 51, 941–951 (2008)CrossRefPubMedGoogle Scholar
- 4.M.I. Maiorino, G. Bellastella, M. Petrizzo, M.R. Improta, C. Brancario, F. Castaldo, L. Olita, D. Giugliano, K. Esposito, Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI. Endocrine (2013). doi: 10.1007/s12020-013-0060-6
- 6.M.L. Misso, K.J. Egberts, M. Page, D. O’Connor, J. Shaw, Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev 1, CD005103 (2008)Google Scholar
- 7.Polish Diabetes Association, Clinical recommendations for the management of patients with diabetes. Clin. Diabetol. 2(Suppl A), 3–52 (2013)Google Scholar
- 10.R.M. Bergenstal, W.V. Tamborlane, A. Ahmann, J.B. Buse, G. Dailey, S.N. Davis, C. Joyce, T. Peoples, B.A. Perkins, J.B. Welsh, S.M. Willi, M.A. Wood, STAR 3 Study Group: effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N. Engl. J. Med. 22(363), 311–320 (2010)CrossRefGoogle Scholar
- 11.R.L. Brazg, T.S. Bailey, S. Garg, B.A. Buckingham, R.H. Slover, D.C. Klonoff, X. Nguyen, J. Shin, J.B. Welsh, S.W. Lee, The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia. J. Diabetes Sci. Technol. 1(5), 1466–1471 (2011)CrossRefGoogle Scholar
- 14.Health Quality Ontario, Continuous subcutaneous insulin infusion (CSII) pumps for Type 1 and Type 2 adult diabetic populations. An evidence-based analysis. Ont. Health Technol. Assess. Ser. 9, 1–58 (2009)Google Scholar
- 15.E.M. Gerstl, W. Rabl, J. Rosenbauer, H. Grobe, S.E. Hofer, U. Krause, R.W. Holl, Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centers in Germany and Austria during the last decade. Eur. J. Pediatr. 167, 447–453 (2008)CrossRefPubMedGoogle Scholar
- 18.B. Bode, R.W. Beck, D. Xing, L. Gilliam, I. Hirsch, C. Kollman, L. Laffel, K.J. Ruedy, W.V. Tamborlane, S. Weinzimer, H. Wolpert, Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes. Diabetes Care 32, 2047–2049 (2009)CrossRefPubMedGoogle Scholar
- 20.A.E. Scaramuzza, D. Iafusco, I. Rabbone, R. Bonfanti, F. Lombardo, R. Schiaffini, P. Buono, S. Toni, V. Cherubini, G.V. Zuccotti, Use of integrated real-time continuous glucose monitoring/insulin pump system in children and adolescents with type 1 diabetes: a 3-year follow-up study. Diabetes Technol. Ther. 13, 99–103 (2011)CrossRefPubMedGoogle Scholar
- 21.J.B. Buse, G. Dailey, A. Ahmann, R.M. Bergenstal, J.B. Green, T. Peoples, R.J. Tanenberg, Q. Yang, Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. Diabetes Technol. Ther. 13, 601–606 (2011)CrossRefPubMedCentralPubMedGoogle Scholar